drugdeliverybusiness5d
Senseonics wins FDA nod for 365-day implantable CGM
Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.
BioWorld5d
FDA clears Senseonic’s Eversense one-year implantable CGM
The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...
Senseonics Holdings, Inc.: Eversense 365 Receives FDA Clearance: The World's First One Year CGM
Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus ...
FierceBiotech5d
FDA clears Senseonics' 365-day Eversense CGM implant
After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...
Future Market Insights5d
Global Insulin Pumps Market Set to Soar with Projected Growth to USD 14.8 Billion by 2032
The global insulin pumps market, valued at USD 5.5 billion in 2022, is poised for remarkable growth, with an anticipated ...
Eversense 365 Receives FDA Clearance: The World’s First One Year CGM
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...